SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Yeung MJ, Serpell JW. Management of the solitary thyroid nodule. Oncologist. 2008; 13: 105-112.
  • 2
    Niedzela M. Pathogenesis, diagnosis, and management of thyroid nodules in children. Endocr Relat Cancer. 2006; 13: 427-453.
  • 3
    Rallison ML, Dobyns BM, Meikle AW, Bishop M, Lyon JL, Stevens W. Natural history of thyroid abnormalities: prevalence, incidence, and regression of thyroid diseases in adolescents and young adults. Am J Med. 1991; 91: 363-370.
  • 4
    Altincik A, Demir K, Abaci A, Bober E, Buyukgebiz A. Fine-needle aspiration biopsy in the diagnosis and follow-up of thyroid nodules in childhood. J Clin Res Pediatr Endocrinol. 2010; 2: 78-80.
  • 5
    Canadian Pediatric Thyroid Nodule Study Group. The Canadian Pediatric Thyroid Nodule Study: an evaluation of current management practices. J Pediatr Surg. 2008; 43: 826-830.
  • 6
    Hoperia V, Larin A, Jensen K, Bauer A, Vasko V. Thyroid fine needle aspiration biopsies in children: study of cytological-histological correlation and immunostaining with thyroid peroxidase monoclonal antibodies. Int J Pediatr Endocrinol. 2010; 2010: 690108.
  • 7
    Raab SS, Silverman JF, Elsheikh TM, Thomas PA, Wakely PE. Pediatric thyroid nodules: disease demographics and clinical management as determined by fine needle aspiration biopsy. Pediatrics. 1995; 95: 46-49.
  • 8
    Cooper DS, Doherty GM, Haugen BR, et al; American Thyroid Association Guidelines Taskforce. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006; 16: 109-142.
  • 9
    Kim DL, Song KH, Kim SK. High prevalence of carcinoma in ultrasonography-guided fine needle aspiration cytology of thyroid nodules. Endocr J. 2008; 55: 135-142.
  • 10
    Papini E, Guglielmi R, Bianchini A, et al. Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features. J Clin Endocrinol Metab. 2002; 87: 1941-1946.
  • 11
    Roy R, Kouniavsky G, Schneider E, et al. Predictive factors of malignancy in pediatric thyroid nodules. Surgery. 2011; 150: 1228-1233.
  • 12
    Arda IS, Yildirim S, Demirhan B, Firat S. Fine needle aspiration biopsy of thyroid nodules. Arch Dis Child. 2001; 85: 313.
  • 13
    Bargren AE, Meyer-Rochow GY, Sywak MS, Delbridge LW, Chen H, Sidhu SB. Diagnostic utility of fine-needle aspiration cytology in pediatric differentiated thyroid cancer. World J Surg. 2010; 34: 1254-1260.
  • 14
    Corrias A, Einaudi S, Chiorboli E, et al. Accuracy of fine needle aspiration biopsy of thyroid nodules in detecting malignancy in childhood: comparison with conventional clinical, laboratory, and imaging approaches. J Clin Endocrinol Metab. 2001; 86: 4644.
  • 15
    Izquierdo R, Shankar R, Kort K, Khurana K. Ultrasound-guided fine-needle aspiration in the management of thyroid nodules in children and adolescents. Thyroid. 2009; 19: 703.
  • 16
    Khozeimeh N, Gingalewski C. Thyroid nodules in children: a single institution's experience. J Oncol. 2011; 2011: 974125.
  • 17
    Stevens C, Lee JKP, Sadatsafavi M, Blair GK. Pediatric thyroid fine-needle aspiration cytology: a meta-analysis. J Pediatr Surg. 2009; 44: 2184-2191.
  • 18
    Baloch ZW, LiVolsi VA, Asa SL, et al. Diagnostic terminology and morphologic criteria for the cytological diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn Cytopathol. 2008; 36: 425-437.
  • 19
    Ali SZ, Cibas ES. The Bethesda System for Reporting Thyroid Cytopathology: definitions, criteria, and explanatory notes. New York, NY: Springer; 2010.
  • 20
    Nikiforov YE, Steward DL, Robinson-Smith TM, et al. Molecular testing for mutations in improving the fine needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab. 2009; 94: 2092-2098.
  • 21
    Nikiforov YE, Ohori NP, Hodak SP, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab. 2011; 96: 3390-3397.
  • 22
    Scholz S, Smith JR, Chaignaud, Shamberger RC, Huang SA. Thyroid surgery at Children's Hospital Boston: a 35-year single-institution experience. J Pediatr Surg. 2011; 46: 437-442.
  • 23
    Bongarzone I, Fugazzola L, Vigneri P, et al. Age-related activation of the tyrosine kinase receptor protooncogenes RET and NTRK1 in papillary thyroid carcinoma. J Clin Endocrinol Metab. 1996; 81: 2006-2009.
  • 24
    Soares P, Fonseca E, Wynford-Thomas D, Sobrinho-Simoes M. Sporadic ret-rearranged papillary carcinoma of the thyroid: a subset of slow growing, less aggressive thyroid neoplasms? J Pathol. 1998; 185: 71-78.
  • 25
    Tallini G, Santoro M, Helie M, et al. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin Cancer Res. 1998; 4: 287-294.
  • 26
    Bounacer A, Wicker R, Caillou B, et al. High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation. Oncogene. 1997; 15: 1263-1273.
  • 27
    Klugbauer S, Lengfelder E, Demidchik EP, et al. High prevalence of RET rearrangement in thyroid tumors of children from Belarus after the Chernobyl reactor accident. Oncogene. 1995; 11: 2459-2467.
  • 28
    Kumagai A, Namba H, Saenko VA, et al. Low frequency of BRAF1796A mutations in childhood thyroid carcinomas. J Clin Endocrinol Metab. 2004; 89: 4280-4284.
  • 29
    Elisei R, Ugolini C, Viola D, et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab. 2008; 93: 3943-3949.
  • 30
    Xing M, Clark D, Guan H, et al. BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol. 2009; 27: 2977-2982.
  • 31
    Singh RS, Wang HH. Eliminating the “atypia of undetermined significance/follicular lesion of undetermined significance” category from the Bethesda System for Reporting Thyroid Cytopathology. Am J Clin Pathol. 2011; 136: 896-902.
  • 32
    Grigsby PW, Gal-or A, Michalski JM, et al. Childhood and adolescent thyroid carcinoma. Cancer. 2002; 95: 724-729.
  • 33
    Ries L, Melbert D, Krapcho M, et al. SEER cancer statistics review. Bethesda, MD: National Cancer Institute; 2008.